SCHEMBL17035474

SCHEMBL17035474

NC(=O)c1cc(CC(=O)N2C[C@H](F)C[C@H]2C(=O)NCc2cccc(Cl)c2F)c2cccccc1-2

nearest known ligand 0.67

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CFD P00746 20/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17035466 0.94 CFD (0.68) CFD
SCHEMBL17035464 0.92 CFD (0.77) CFD
SCHEMBL18826370 0.90 CFD (0.56) CFD
SCHEMBL17032874 0.85 CFD (0.72) CFD
SCHEMBL18826371 0.84 CFD (0.55) CFD
SCHEMBL18826378 0.82 CFD (0.63) CFD
SCHEMBL19216059 0.82 CFD (0.68) CFD
SCHEMBL19216056 0.82 CFD (0.59) CFD
SCHEMBL17023343 0.81 CFD (0.64) CFD
SCHEMBL12480252 0.80 CFD (1.00) CFD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170226142-A1 Factor D Inhibitors Useful for Treating Inflammatory Disorders ACHILLION PHARMACEUTICALS, INC. (US) 2017-08-10 US disclosed
US-20170226142-A1 Factor D Inhibitors Useful for Treating Inflammatory Disorders ACHILLION PHARMACEUTICALS, INC. (US) 2017-08-10 US disclosed
US-9643986-B2 Factor D inhibitors useful for treating inflammatory disorders ACHILLION PHARMACEUTICALS, INC. (US) 2017-05-09 US disclosed
US-20150239837-A1 Factor D Inhibitors Useful for Treating Inflammatory Disorders ACHILLION PHARMACEUTICALS, INC. (US) 2015-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150239837-A1 Factor D Inhibitors Useful for Treating Inflammatory Disorders CFD, TFPI, TFPI2 CFD 1/4885
US-20170226142-A1 Factor D Inhibitors Useful for Treating Inflammatory Disorders CFD, TFPI, TFPI2 CFD 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.